Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; lactose monohydrate; magnesium stearate; purified talc; hyprolose; titanium dioxide; iron oxide yellow; xanthan gum; polyvinyl alcohol; iron oxide black; lecithin; indigo carmine aluminium lake - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - - treatment of schizophrenia and related psychoses. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder.. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; carmellose calcium; sucralose; mannitol - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: carmellose calcium; sucralose; mannitol; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose monohydrate; magnesium stearate; crospovidone - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; hyprolose - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.